705 related articles for article (PubMed ID: 33812495)
1. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors.
Waissengrin B; Agbarya A; Safadi E; Padova H; Wolf I
Lancet Oncol; 2021 May; 22(5):581-583. PubMed ID: 33812495
[No Abstract] [Full Text] [Related]
2. Safety and immunogenicity after 2 doses of the BNT162b2 COVID-19 vaccine in an early-phase oncology trial centre population.
Malissen N; Ninove L; de Lamballerie X; André N; Gaudy-Marqueste C
Eur J Cancer; 2021 Oct; 156():125-126. PubMed ID: 34438245
[No Abstract] [Full Text] [Related]
3. SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: Recommendations from the French society for ImmunoTherapy of Cancer (FITC).
Gauci ML; Coutzac C; Houot R; Marabelle A; Lebbé C;
Eur J Cancer; 2021 May; 148():121-123. PubMed ID: 33743480
[No Abstract] [Full Text] [Related]
4. The mRNA COVID-19 vaccine in patients with cancer receiving checkpoint inhibitor therapy: what we know and what we don't.
Malek AE; Cornejo PP; Daoud N; Alam M
Immunotherapy; 2022 Feb; 14(2):91-94. PubMed ID: 34747190
[No Abstract] [Full Text] [Related]
5. Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors.
Terpos E; Zagouri F; Liontos M; Sklirou AD; Koutsoukos K; Markellos C; Briasoulis A; Papanagnou ED; Trougakos IP; Dimopoulos MA
J Hematol Oncol; 2021 May; 14(1):86. PubMed ID: 34059088
[TBL] [Abstract][Full Text] [Related]
6. Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options: A retrospective single-center study.
Kian W; Zemel M; Kestenbaum EH; Rouvinov K; Alguayn W; Levitas D; Ievko A; Michlin R; Abod MA; Massalha I; Chernomordikov E; Sharb AA; Shalata W; Levison E; Roisman LC; Lavrenkov K; Peled N; Nesher L; Yakobson A
Medicine (Baltimore); 2022 Jan; 101(2):e28561. PubMed ID: 35029223
[TBL] [Abstract][Full Text] [Related]
7. Short-term Adverse Events After the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine in Adults 60 Years or Older.
Auster O; Finkel U; Dagan N; Barda N; Laufer A; Balicer RD; Ben-Shachar S
JAMA Netw Open; 2022 Apr; 5(4):e227657. PubMed ID: 35435973
[TBL] [Abstract][Full Text] [Related]
8. Type 1 Diabetes Mellitus Associated with Nivolumab after Second SARS-CoV-2 Vaccination, Japan.
Sato T; Kodama S; Kaneko K; Imai J; Katagiri H
Emerg Infect Dis; 2022 Jul; 28(7):1518-1520. PubMed ID: 35468049
[TBL] [Abstract][Full Text] [Related]
9. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
Front Immunol; 2021; 12():704773. PubMed ID: 34220867
[TBL] [Abstract][Full Text] [Related]
10. Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.
Benda M; Mutschlechner B; Ulmer H; Grabher C; Severgnini L; Volgger A; Reimann P; Lang T; Atzl M; Huynh M; Gasser K; Petrausch U; Fraunberger P; Hartmann B; Winder T
Br J Haematol; 2021 Nov; 195(4):523-531. PubMed ID: 34346068
[TBL] [Abstract][Full Text] [Related]
11. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
[TBL] [Abstract][Full Text] [Related]
12. Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine.
Yamamoto S; Fukunaga A; Tanaka A; Takeuchi JS; Inoue Y; Kimura M; Maeda K; Ueda G; Mizoue T; Ujiie M; Sugiura W; Ohmagari N
Vaccine; 2022 Mar; 40(13):1924-1927. PubMed ID: 35183384
[TBL] [Abstract][Full Text] [Related]
13. Indications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination.
Luo B; Li J; Hou X; Yang Q; Zhou Y; Ye J; Wu X; Feng Y; Hu T; Xu Z; He Y; Sun J
Future Oncol; 2021 Sep; 17(26):3477-3484. PubMed ID: 34189948
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up.
Lasagna A; Lilleri D; Agustoni F; Percivalle E; Borgetto S; Alessio N; Comolli G; Sarasini A; Bergami F; Sammartino JC; Ferrari A; Zavaglio F; Arena F; Secondino S; Falzoni M; Schiavo R; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
ESMO Open; 2022 Feb; 7(1):100359. PubMed ID: 34973510
[TBL] [Abstract][Full Text] [Related]
15. Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection.
Nemet I; Kliker L; Lustig Y; Zuckerman N; Erster O; Cohen C; Kreiss Y; Alroy-Preis S; Regev-Yochay G; Mendelson E; Mandelboim M
N Engl J Med; 2022 Feb; 386(5):492-494. PubMed ID: 34965337
[No Abstract] [Full Text] [Related]
16. A flare of pre-existing erythema multiforme following BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine.
Lavery MJ; Nawimana S; Parslew R; Stewart L
Clin Exp Dermatol; 2021 Oct; 46(7):1325-1327. PubMed ID: 33914926
[No Abstract] [Full Text] [Related]
17. Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine.
Tarawneh O; Tarawneh H
Am J Hematol; 2021 May; 96(5):E133-E134. PubMed ID: 33476455
[No Abstract] [Full Text] [Related]
18. Thrombocytopenia after COVID-19 vaccination.
Kragholm K; Sessa M; Mulvad T; Andersen MP; Collatz-Christensen H; Blomberg SN; Lippert F; Mikkelsen S; Leutscher P; Melgaard D; Torp-Pedersen C; Kristensen SR; Larsen TB; Sogaard P
J Autoimmun; 2021 Sep; 123():102712. PubMed ID: 34332437
[No Abstract] [Full Text] [Related]
19. Worsening of the vitiligo following the second dose of the BNT162B2 mRNA COVID-19 vaccine.
Okan G; Vural P
Dermatol Ther; 2022 Mar; 35(3):e15280. PubMed ID: 34931408
[No Abstract] [Full Text] [Related]
20. Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273.
Steensels D; Pierlet N; Penders J; Mesotten D; Heylen L
JAMA; 2021 Oct; 326(15):1533-1535. PubMed ID: 34459863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
